Methoxsalen

Evidence Level: L5

Predicted Indications: 8

Methoxsalen

Pharmacist Assessment Report

Methoxsalen: From Cutaneous T-Cell Lymphoma and Vitiligo to Localized Pagetoid Reticulosis

One-Sentence Summary

Methoxsalen is a photosensitising agent originally used for primary cutaneous T-cell lymphoma and vitiligo. The TxGNN model predicts it may be effective for localized pagetoid reticulosis (an indolent variant of mycosis fungoides), but there are currently 0 clinical trials and 0 publications specific to this disease. The prediction is supported by model scoring and biological plausibility only.

Quick Overview

Item	Content
Original Indication	Primary cutaneous T-cell lymphoma; vitiligo (the ARTG entry in the data compiled for this report has no indication text)
Predicted New Indication	Localized pagetoid reticulosis
TxGNN Prediction Score	0.9997
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, methoxsalen is a psoralen. It is used with UVA light (PUVA) and in extracorporeal photopheresis. It intercalates into DNA and, once activated by UVA, forms crosslinks that induce apoptosis in malignant T cells.

Localized pagetoid reticulosis (Woringer-Kolopp disease) is an indolent variant of mycosis fungoides, which is a primary cutaneous T-cell lymphoma. Because methoxsalen is already used in cutaneous T-cell lymphoma, the biological rationale is plausible. However, the high TxGNN score (0.9997) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not independent evidence of efficacy.

The other top predictions are mostly B-cell lymphomas, deep-seated extranodal lymphomas and a benign skin lesion. They have no plausible mechanistic link to UVA photochemotherapy and are not discussed further.

Clinical Trial Evidence

Currently no related clinical trials registered for localized pagetoid reticulosis. No trials were found for the other top-ranked predictions either.

Literature Evidence

No literature specific to localized pagetoid reticulosis is available. The only supporting publication relates to the rank 2 prediction, indolent primary cutaneous T-cell lymphoma, and is indirect evidence:

PMID	Year	Type	Journal	Key Findings
23074497	2006	Review	Ontario Health Technology Assessment Series	Evidence-based analysis of the effectiveness, safety and cost-effectiveness of extracorporeal photopheresis for refractory erythrodermic CTCL and refractory chronic graft-versus-host disease

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 12154Q	Uvadex	Solution for blood fraction, 20 microgram per mL, 10 mL	Not stated in the data compiled for this report

The only registered route is “Other” (a solution for blood fraction, consistent with extracorporeal use). It has not been assessed whether this is suitable for the predicted indication.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Photosensitising agent (psoralen) activated by UVA. Not a conventional cytotoxic, but the effect on malignant T cells is DNA crosslinking and apoptosis.
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the Product Information (PI) warnings and precautions
Handling Protection	Please refer to the Product Information (PI) warnings and precautions

Safety Considerations

Label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.

Contraindications suggested by the knowledge graph (these come from the knowledge graph, not from label text, and need verification against the PI):
- Photosensitivity conditions: photosensitivity disease, photoparoxysmal response
- Porphyrias: including porphyria cutanea tarda, variegate porphyria and erythropoietic protoporphyria
- Skin cancers: melanoma, basal cell carcinoma, squamous cell carcinoma and other carcinomas
- Other: liver disease, gallbladder disease, systemic lupus erythematosus, xeroderma pigmentosum, albinism, Waardenburg syndrome, piebaldism, Griscelli syndrome and peroxisome biogenesis disorder
Drug Interactions: 100 interactions were found, and the 20 retrieved are all Moderate severity. They include:
- Tetracyclines: doxycycline, tetracycline, minocycline
- Sulfonylureas: chlorpropamide, glimepiride, glipizide, glyburide, tolbutamide, tolazamide, acetohexamide
- Others: levofloxacin, sulfasalazine, promethazine, ibuprofen, flurbiprofen, alosetron
Many of these are photosensitising or hypoglycaemic agents. Concurrent use with a psoralen needs review.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for localized pagetoid reticulosis rests on a model score and a plausible link to the existing CTCL indication. There are no trials or publications specific to this disease (Evidence Level L5). Safety data from the label are also missing. The rank 2 prediction (indolent CTCL) is better framed as a research question within the existing CTCL indication, with only indirect evidence.

To proceed, the following is needed:

Case series, registry data or literature on PUVA or photopheresis in localized pagetoid reticulosis
Mechanism of action data (for example from DrugBank)
The TGA Product Information, including indications, warnings, contraindications and the approved route and use of Uvadex
A check of the knowledge-graph contraindications (especially skin cancer history and photosensitivity) against the PI
Confirmation of whether the existing Uvadex use already covers this disease within the CTCL indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.